Carving your way through the resistance minefield
2006-10-26 - English

Facing An Epidemic of Multidrug Resistant Tuberculosis
2007-10-24 - English

HIV Treatment and Prevention: Facing the Future
2007-10-24 - English

How to Best Sequence PI's
2007-10-25 - English

Switching from Combivir[CBV] (AZT/3TC) to Truvada [TVD] (Tenofovir DF/FTC) Maintains Viral Suppression, Prevents and Reverses Limb Fat Loss, and Improves Biochemical Parameters: Results of a 48 Week Randomised Study
2007-10-25 - English

Improvement of Survival after a Neurological AIDS Defining Event over Time
2007-10-25 - English

HIV Is My Disease
2007-10-25 - English

Prognostic Factors of Virological Success in Antiretroviral-naïve Patients Receiving LPV/r Monotherapy in the MONARK Trial
2007-10-25 - English

Should HIV Treatment Be Started Sooner?
2007-10-25 - English

Saquinavir/r (SQV/r) BID versus Lopinavir/r (LPV/r) BID, Plus Emtricitabine/Tenofovir (FTC/TDF) QD as Initial Therapy in HIV-1-infected Patients: The Gemini Study
2007-10-25 - English

HIV-Infection Increases Cystatin C Concentrations Leading to an Underestimation of Glomerular Filtration Rate
2007-10-25 - English

Frequency of Smear-positive and Drug Resistant Tuberculosis in HIV-infected atients in St. Petersburg, Russia
2007-10-25 - English

Early and Late Newly Diagnosed HIV Infections
2007-10-25 - English

Survival and Risk of Death among HIV-infected Patients who Diagnosed Cryptococcal Meningitis with/without Antiretroviral Therapy in a Resource-Limited Settings
2007-10-25 - English

Does Diabetes Mellitus (DM) Confer a Risk or Coronary Heart Disease (CHD) Equivalent to that of prior CHD in HIV-positive Individuals?
2007-10-25 - English

Which Indicator Diseases?
2007-10-25 - English

Use of Indicator Diseases to Optimize Testing
2007-10-25 - English

Terminal Differentiation of HIV-specific T Cell Responses is Restricted to Distinct Clonotypes with Low CD57 Expression
2007-10-25 - English

Influence of the Toll-like Receptor 9 1635 C/T Polymorphism on CD4 Count, HIV Viral Load and Clinical Progression
2007-10-25 - English

Protease Inhibitor Resistance Mutations Influence Recognition of Protease by HIV-1-Specific CTL
2007-10-25 - English

Antigen-specific T Lymphocytes with High Proliferative Capacity Inversely Correlate with Viral Replication in Chronically Untreated HIV-1-infected Individuals
2007-10-25 - English

Lopinavir-ritonavir Monotherapy vs Lopinavir-ritonavir and Two Nucleosides for Maintenance Therapy of HIV. Ninety-six Week Results of a Randomized, Controlled, Open Label, Clinical Trial (OK04 Study)
2007-10-25 - English

Boosted or Unboosted Atazanavir as Simplification of Lopinavir/r-containing Regimens
2007-10-25 - English

When, Why and How to Change Therapy
2007-10-25 - English

Nevirapine in Combination with Atazanavir/Ritonavir as a Nucleoside-sparing Regimen in HIV-infected-antiretroviral Experienced Subjects with Sustained Virologic Suppression (NEVATA Study)
2007-10-25 - English

Prospective HLA-B*5701 Screening Significantly Reduces the Incidence of Abacavir Hypersensitivity Reactions (ABC HSR) in Patients Treated with ABC-Containing HAART
2007-10-25 - English

Antiretroviral Changes after Viral Load Rebound in the UK Collaborative HIV Cohort (CHIC) Study
2007-10-25 - English

Triggers to Modifying Treatment
2007-10-25 - English

Trends in Transmitted Drug Resistance among Different Routes of Infection and Seroconverters as Defined by an Antibody Avidity Assay
2007-10-25 - English

Mutations Associated with Virologic Response to Darunavir/ritonavir in HIV-1-infected PI-experienced Patients
2007-10-25 - English

Transmission of HIV Drug Resistance to NNRTIs Occurs within Clusters
2007-10-25 - English

Continuation of BID Boosted PI vs Switch to Once-daily ATV/RTV for the Management of Lipodystrophy: 24-Week Interim Analysis of Metabolic and Inflammatory Parameters of the 96-Week Multicenter, Open-label, Randomised, Prospective Real Study
2007-10-25 - English

Non-alcoholic Fatty Liver Disease (NAFLD) in HIV Infected Patients: Prevalence, Characteristics and Predictors
2007-10-25 - English

Factors associated to diagnosis of NAFLD in HIV infected patients

The Pro12Ala Polymorphism of Peroxisome Proliferator Activated Receptor Gene y-2 (PPAR Gamma-2) is Associated with Increased Insulin Sensitivity in HIV-infected Patients on Antiretroviral Therapy
2007-10-25 - English

Genetic factors may modulate insulin resistance in HIV patients on ART

Efficacy and Safety of Maraviroc (MVC) Plus Optimized Background Therapy (OBT) in Viraemic, Antiretroviral Treatment-Experienced Patients Infected with CCR5-Tropic (R5) HIV-1 in Europe, Australia and North America (MOTIVATE 2): 48-Week Results
2007-10-25 - English

HIV-1 Genotypic Resistance during Intermittent Antiretroviral Therapy and its Impact on CD4 Cell Counts and Antiviral Response. A Substudy of the ANRS 106 Window Trial
2007-10-25 - English

Incidence of Nevirapine-associated Hypersensitivity Reactions in Once Daily versus Twice Daily Regimen. A Collaborative Cohort Study
2007-10-25 - English

Clinical Pharmacology of the HIV Integrase Inhibitor Elvitegravir
2007-10-25 - English

Pharmacokinetics (PK) ofatazanavir/ritonavir (ATV/r) once daily (OD) and lopinavir/ritonavir (LPV/r) twice daily (BD) and ODover 72 hours following drug intake cessation
2007-10-26 - English

The importance of half life and drug persistance when advising HIV patients on once daily regimens

Clinical Case 2 - Hepatitis C
2007-10-26 - English

Clinical Case 1 - Hepatitis B
2007-10-26 - English

Clinical Case 2 - Naive ART Patient with Marginal Increased Risk of CVD
2007-10-26 - English

Does Hepatitis C Virus (HCV) Genotype or Viral Load Predict the Risk of All-cause Mortality or HIV/HCV Coinfection?
2007-10-26 - English

Pre-exposure Prophylaxis(PrEP): State-of-the-art
2007-10-26 - English

Introduction to Hepatitis Treatment Guidelines
2007-10-26 - English

New Drugs on the Horizon for Treatment of Viral Hepatitis
2007-10-26 - English

ARTEMIS: Efficacy and safety of lopinavir (BID vs QD) and darunavir (QD) in antiretroviral-naïve patients
2007-10-26 - English

Virologic Suppression Is Maintained After Change To Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (EFV/FTC/TDF) vs. Continuation of Current Antiretroviral Therapy: Study 073 -Results of 24-week Interim Efficacy Analyses
2007-10-26 - English

Predicting the CD4 Slope in Patients Starting cART after 1st January 1999
2007-10-26 - English

Epidemiological and Virological Characteristics of Chronic Hepatitis C (HCV) within the EuroSIDA Observational Cohort
2007-10-26 - English

Growing Old with HIV
2007-10-26 - English

Long-Term Safety and Efficacy of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor (GRF) Analogue, in HIV-Infected Patients with Abdominal Fat Accumulation
2007-10-26 - English

A prospective, randomized, open label trial comparing the efficacy and safety of rosuvastatin versus pravastatin in HIV-infected subjects receiving ritonavir boosted PI with lipid abnormalities.
2007-10-26 - English

High rates of primary resistance to NNRTI among patients with HIV-1 non-B clades infection in Switzerland
2007-10-26 - English

Clinical Case 1 . Treatment on a pregnant woman with low CD4
2007-10-26 - English

Clinical Case 1 . Extensive ART History and Multiple Metabolic Disturbances
2007-10-26 - English

Introduction to HIV Treatment Guidelines
2007-10-26 - English

Patient case: 2nd failure to ARV therapy
2007-10-26 - English

Effects of Immunoadjuvant Therapy with IL-2 in HIV-Positive HAART-Naive Patients in Advanced Stage of Disease: A Characterization of the Diverse Immunological Responses to IL-2
2007-10-26 - English

Clinical Consequences of Discordant Immuno-/ Virological Responses in Patients Initiating HAART at Severe Immunodeficiency
2007-10-26 - English

A Randomized, Controlled, Phase II Study with an MVA-nef Vaccine in HIV-1 Infected Patients Followed by Structured Treatment Interruption (STI)
2007-10-26 - English

Objective: MVA-BN, a viral vector which is safe and fails to replicate in human cells, has shown potent ability to induce cell mediated immune response in previous phase I/II studies. This phase II trial was initiated to assess the immunogenicity and safety of the...(more)

Morbidity and Mortality in HIV Infected Patients with Compensated and Decompensated Cirrhosis: Prospective Cohort of 373 Patients
2007-10-26 - English

Long-term Impact of Interferon (IFN)-based Therapy on Liver-related Decompensation, Hepato-Cellular Carcinoma (HCC) and Liver Death in HIV/HCV Co-infected Patients: A Retrospective Cohort Study (Intercept)
2007-10-26 - English

HIV Vaccines: State-of-the-art
2007-10-26 - English

Male Circumcision
2007-10-26 - English

The Natural History of Acute Hepatitis C (AHC) in HIV Co-infected Individuals . A European Collaborative Study
2007-10-26 - English

Liver Disease in HIV: What Lies Ahead?
2007-10-27 - English

Will new drugs change treatment paradigms?
2007-10-27 - English

Does HIV Therapy Affect Normal Aging?
2007-10-27 - English

Assessing and Managing CVD in HIV
2007-10-27 - English

The ageing patient with HIV... Assessing and managing renal disease in HIV
2007-10-27 - English

Use the appropriate tools to diagnose chronic kidney disease in HIV patients
Discuss the main causes of HIV associated renal diseases
Discuss the main antiretroviral drug induced renal consequences
Use the main recommandations with regard to antiretroviral drug dosage adaptation

Cancer and HIV: What Does the Future Hold?
2007-10-27 - English